年轻乳腺癌女性他莫昔芬使用与子宫疾病风险
该回顾性队列研究采用目标试验模拟框架,纳入台湾2010至2019年确诊的20-50岁雌激素受体阳性乳腺癌术后患者,比较他莫昔芬辅助治疗组与非治疗组的子宫疾病风险,发现他莫昔芬使用与子宫内膜息肉、增生及癌风险升高相关,且风险随用药时间延长而增加。
要点
- 他莫昔芬辅助治疗与子宫内膜息肉、增生及癌风险升高相关
- 按方案分析中子宫内膜癌风险显著升高(HR 4.20,95%CI 1.20-14.63)
- 子宫疾病总体风险随他莫昔芬使用时间延长而增加
核心结论
- 在台湾绝经前乳腺癌女性中,他莫昔芬作为辅助激素治疗与子宫疾病(包括子宫内膜癌)风险升高相关,提示对该年龄段用药者应监测子宫疾病。
研究设计与样本
- 回顾性队列研究,采用目标试验模拟框架,基于台湾全民健康保险申报数据链接癌症登记库。
- 纳入2010至2019年确诊的20-50岁雌激素受体阳性乳腺癌且接受乳房切除或肿块切除的女性,排除子宫切除史、新辅助治疗、绝经状态及子宫疾病诊断者。
- 他莫昔芬使用定义为术后1年内仅接受他莫昔芬作为辅助激素治疗;采用逆概率治疗加权控制基线混杂,以合并逻辑回归模型估计意向治疗和按方案效应的观察性类似值。
主要发现
- 共纳入23,062名他莫昔芬使用者和3,000名非使用者;随访期间分别有3,889名使用者和109名非使用者发生子宫疾病,其中子宫内膜癌分别为106例和5例。
- 意向治疗分析中,子宫内膜息肉的风险比为4.15(95%CI 2.65-6.50),子宫内膜增生为5.42(95%CI 4.09-7.18),子宫内膜癌为2.41(95%CI 0.86-6.72)。
- 按方案分析中,对应估计值分别为4.75(95%CI 2.55-8.86)、8.37(95%CI 5.24-13.35)和4.20(95%CI 1.20-14.63)。
- 所有子宫疾病的风险随他莫昔芬使用时间延长而增加。
临床怎么用
- 对绝经前乳腺癌患者使用他莫昔芬辅助治疗时,应关注子宫内膜息肉、增生及癌的风险,并进行相应监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tamoxifen use has been associated with an increased risk of endometrial cancer in women with breast cancer, but data on premenopausal women in Asia remain limited. We investigated the association between tamoxifen treatment and risk of developing uterine diseases in women of premenopausal age with breast cancer. METHODS: We conducted a retrospective cohort study using a target trial emulation framework. Women aged 20-50 years who were diagnosed with estrogen receptor-positive breast cancer and had undergone mastectomy or lumpectomy from 2010 to 2019 were identified with Taiwan's National Health Insurance claims data linked to the cancer registry. Those with a history of hysterectomy, neoadjuvant therapy, and diagnosis of postmenopausal status and uterine diseases were excluded. Tamoxifen use was defined as receipt tamoxifen treatment only as adjuvant hormone treatment within 1 year after surgery. Inverse probability of treatment weighting controlled baseline confounding between the tamoxifen treatment and nontreatment groups. Observational analogs of the intention-to-treat and per-protocol effects were estimated with pooled logistic regression models. RESULTS: A total of 23,062 tamoxifen users and 3,000 nonusers were included. During the follow-up period, 3,889 users and 109 nonusers developed uterine diseases, including 106 and 5 cases of endometrial cancer, respectively. In the intention-to-treat analysis, the hazard ratio was 4.15 (95% CI, 2.65-6.50) for endometrial polyps, 5.42 (95% CI, 4.09-7.18) for endometrial hyperplasia, and 2.41 (95% CI, 0.86-6.72) for endometrial cancer. Corresponding estimates from the per-protocol analysis were 4.75 (95% CI, 2.55-8.86), 8.37 (95% CI, 5.24-13.35), and 4.20 (95% CI, 1.20-14.63), respectively. The risk of all uterine diseases increased with longer duration of tamoxifen use. CONCLUSION: Among women of premenopausal age with breast cancer in Taiwan, tamoxifen as adjuvant hormone therapy was associated with increased risk of uterine diseases, including endometrial cancer. These findings highlight the importance of monitoring uterine diseases among tamoxifen users in this age range.
引用
- Yeh YC, Chen PC, Huang HY, et al. Tamoxifen Use and Risk of Uterine Diseases in Young Women With Breast Cancer. Obstet Gynecol. 2026. PMID: 41785462. doi:10.1097/AOG.0000000000006238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。